Armistice Capital’s Minerva Neurosciences NERV Stock Holding History

Armistice Capital’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-128,000	Closed	-$850K	–	193
2022 Q1	$850K	Hold	128,000	–	–	0.02%	112
2021 Q4	$820K	Buy	128,000 +3,000	+2%	+$28.2K	0.01%	129
2021 Q3	$1.74M	Buy	125,000 +11,000	+10%	+$165K	0.03%	120
2021 Q2	$2.12M	Hold	114,000	–	–	0.04%	103
2021 Q1	$2.66M	Buy	114,000 +51,500	+82%	+$1.29M	0.06%	98
2020 Q4	$1.17M	Hold	62,500	–	–	0.04%	95
2020 Q3	$1.59M	Buy	62,500 +25,000	+67%	+$676K	0.06%	91
2020 Q2	$1.08M	Hold	37,500	–	–	0.05%	76
2020 Q1	$1.81M	Sell	37,500 -32,500	-46%	-$1.96M	0.11%	71
2019 Q4	$3.98M	Buy	+70,000	New	+$3.09M	0.23%	65
2015 Q2	–	Sell	-25,329	Closed	-$1.01M	–	31
2015 Q1	$1.01M	Buy	+25,329	New	+$1.05M	0.45%	27

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SEI Investments Oaks, Pennsylvania $108B AUM 26.14% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Armistice Capital's NERV Position: Q2 2022 in Review

Armistice Capital sold out of Minerva Neurosciences (NERV) in Q2 2022, closing a stake of 128,000 shares — an estimated $850K sold.

Armistice Capital first reported a position in NERV in Q1 2015 and held it in 11 quarters. The position peaked at $3.98M in Q4 2019. 23 funds tracked by Wall St. Rank hold NERV as of Q2 2022.

Armistice Capital reported no remaining Minerva Neurosciences position as of Q2 2022 after selling out during the quarter.
Armistice Capital sold 128,000 Minerva Neurosciences shares in Q2 2022, an estimated $850K.
Armistice Capital first reported a position in Minerva Neurosciences in Q1 2015 and held it in 11 quarters.
Armistice Capital's Minerva Neurosciences position peaked at $3.98M in Q4 2019.
23 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2022.

Based on Armistice Capital's 13F filing for Q2 2022, filed 15 Aug 2022.